Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 7/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 7/20 | 0.42 |
| ▸ | CDK2 | P24941 | 6/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.35 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.35 |
| ▸ | MYLK | Q15746 | 1/20 | 0.35 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956090 | 0.91 | PTGS1 (0.36) | CDC7DBF4PTGS1PTGS2MAPK14 | |
| SCHEMBL956417 | 0.90 | CDC7 (0.51) | CDC7DBF4CDK2CCNE1JAK2 | |
| SCHEMBL952522 | 0.89 | CDC7 (0.39) | CDC7DBF4PTGS1PTGS2RAB9A | |
| SCHEMBL958106 | 0.86 | EGFR (0.45) | CDC7DBF4CDK2CCNE1PTGS1 | |
| SCHEMBL955337 | 0.86 | CDC7 (0.46) | CDC7DBF4CDK2CCNE1JAK2 | |
| SCHEMBL956834 | 0.86 | TRPM8 (0.43) | CDC7DBF4CDK2CCNE1JAK2 | |
| SCHEMBL955010 | 0.85 | CDC7 (0.40) | CDC7DBF4CDK2CCNE1MAPK14 | |
| SCHEMBL952856 | 0.83 | CDC7 (0.54) | CDC7DBF4CDK2CCNE1CSF1R | |
| SCHEMBL954019 | 0.83 | HTT (0.39) | CDC7DBF4CDK2CCNE1JAK2 | |
| SCHEMBL953082 | 0.82 | CDC7 (0.42) | CDC7DBF4CDK2CCNE1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | CDC7 601/4885DBF4 3288/4885CDK2 151/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | CDC7 1063/4885DBF4 3779/4885CDK2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.